TY - JOUR
T1 - Treatment results of 165 pediatric patients with non-metastatic nasopharyngeal carcinoma
T2 - A Rare Cancer Network study
AU - Ozyar, Enis
AU - Selek, Ugur
AU - Laskar, Siddihartha
AU - Uzel, Omer
AU - Anacak, Yavuz
AU - Ben-Arush, Miriam
AU - Polychronopoulou, Sopiha
AU - Akman, Fadime
AU - Wolden, Suzanne L.
AU - Sarihan, Süreyya
AU - Miller, Robert C.
AU - Ozsahin, Mahmut
AU - Abacioǧlu, Ufuk
AU - Martin, Margarita
AU - Caloglu, Murat
AU - Scandolaro, Luciano
AU - Szutowicz, Eva
AU - Atahan, Ibtisam Lale
PY - 2006/10
Y1 - 2006/10
N2 - Purpose: This Rare Cancer Network (RCN) study was performed in pediatric nasopharyngeal carcinoma (PNPC) patients to evaluate the optimal dose of radiotherapy and to determine prognostic factors. Patients and Methods: The study included 165 patients with the diagnosis of PNPC treated between 1978 and 2003. The median age was 14 years. There were 3 (1.8%) patients with stage I, 1 (0.6%) with IIA, 10 (6.1%) with IIB, 60 (36.4%) with III, 44 (26.7%) with IVA, and 47 (29%) with IVB disease. While 21 (12.7%) patients were treated with radiotherapy (RT) alone, 144 (87.3%) received chemotherapy and RT. The median follow-up time was 48 months. Results: The actuarial 5-year overall survival (OS) was 77.4% (95% CI: 70.06-84.72), whereas the actuarial 5-year disease-free survival (DFS) rate was 68.8% (95% CI: 61.33-76.31). In multivariate analysis, unfavorable factors were age >14 years for LRC (p = 0.04); male gender for DMFS (p = 0.03); T3/T4 disease for LRFS (p = 0.01); and N3 disease for DFS (p = 0.002) and OS (p = 0.002); EBRT dose of less than 66 Gy for LRFS (p = 0.02) and LRRFS (p = 0.0028); and patients treated with RT alone for LRFS (p = 0.0001), LRRFS (p = 0.007) and DFS (p = 0.02). Conclusion: Our results support the current practice of using combined radiation and chemotherapy for optimal treatment of NPC. However, research should be encouraged in an attempt to reduce the potential for long-term sequelae in pediatric patients given their relatively favorable prognosis and potential for longevity.
AB - Purpose: This Rare Cancer Network (RCN) study was performed in pediatric nasopharyngeal carcinoma (PNPC) patients to evaluate the optimal dose of radiotherapy and to determine prognostic factors. Patients and Methods: The study included 165 patients with the diagnosis of PNPC treated between 1978 and 2003. The median age was 14 years. There were 3 (1.8%) patients with stage I, 1 (0.6%) with IIA, 10 (6.1%) with IIB, 60 (36.4%) with III, 44 (26.7%) with IVA, and 47 (29%) with IVB disease. While 21 (12.7%) patients were treated with radiotherapy (RT) alone, 144 (87.3%) received chemotherapy and RT. The median follow-up time was 48 months. Results: The actuarial 5-year overall survival (OS) was 77.4% (95% CI: 70.06-84.72), whereas the actuarial 5-year disease-free survival (DFS) rate was 68.8% (95% CI: 61.33-76.31). In multivariate analysis, unfavorable factors were age >14 years for LRC (p = 0.04); male gender for DMFS (p = 0.03); T3/T4 disease for LRFS (p = 0.01); and N3 disease for DFS (p = 0.002) and OS (p = 0.002); EBRT dose of less than 66 Gy for LRFS (p = 0.02) and LRRFS (p = 0.0028); and patients treated with RT alone for LRFS (p = 0.0001), LRRFS (p = 0.007) and DFS (p = 0.02). Conclusion: Our results support the current practice of using combined radiation and chemotherapy for optimal treatment of NPC. However, research should be encouraged in an attempt to reduce the potential for long-term sequelae in pediatric patients given their relatively favorable prognosis and potential for longevity.
KW - Nasopharynx cancer
KW - Pediatric
KW - Radiotherapy
KW - Rare
UR - http://www.scopus.com/inward/record.url?scp=33749443724&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33749443724&partnerID=8YFLogxK
U2 - 10.1016/j.radonc.2006.08.019
DO - 10.1016/j.radonc.2006.08.019
M3 - Article
C2 - 16965827
AN - SCOPUS:33749443724
SN - 0167-8140
VL - 81
SP - 39
EP - 46
JO - Radiotherapy and Oncology
JF - Radiotherapy and Oncology
IS - 1
ER -